JPRN-UMIN000030030招募中2 期
TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial - TAS-CC4 Study
Department of Digestive Surgery,Nippon Medical School0 个研究点目标入组 45 人开始时间: 2018年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1)contraindications for TAS-102 and Bevacizumab 2)previously received chemotherapy with TAS-102 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has important clinical complications(symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)other active malignancies 7)have pleural effusion and ascitic fluid with the treatment 8)Comorbidity or history of heart failure 9)gastrointestinal ulcer or bleeding 10)previous hemoptysis 11)Clinical or radiological evidence of CNS metastases 12)Current or previous (within the last 6 months) history of GI perforation 13)Patient with interstitial pneumonia or lung fibrosis confirmed in imaging study 14)ongoing treatment with anticoagulant 15)Synchronous or metachronous multiple malignancy within the last 5 year disease free interval 16)Under continuous steroid administration 17)decision of unsuitable for this study by the investigator
研究者
相似试验
尚未招募
2 期
TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trialmetastatic colorectal cancerJPRN-UMIN000022438Teikyo University Chiba Medical Center31
尚未招募
2 期
TAS-102 and Bevacizumab as second line chemotherapy for colorectal cancer. Phase 2 trialmetastatic colorectal cancerJPRN-UMIN000022437Teikyo University Chiba Medical Center20
已完成
2 期
TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancerColorectal CancerJPRN-UMIN000031790Surgical Oncology Association in Chiba (SOAC)45
已完成
2 期
TAS-CC4 Studycolorectal cancerJPRN-jRCTs031180424Yamada Takeshi45
尚未招募
2 期
TAS-102 plus Bevacizumab combination as salvage therapy in elderly patients with metastatic colorectal cancer, phase 2 trialmetastatic colorectal cancerJPRN-UMIN000021664Tokushima University Hospital25
